Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. more
Time Frame | ATRA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.06% | -3.39% | 0.2% |
1-Month Return | -8.65% | -1.92% | 2.72% |
3-Month Return | 21.62% | -10.54% | 7.31% |
6-Month Return | -2.47% | -4.47% | 10.44% |
1-Year Return | -27.69% | 4.06% | 27.53% |
3-Year Return | -97.27% | 0.94% | 30.88% |
5-Year Return | -97.31% | 36.67% | 89.21% |
10-Year Return | -98.63% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 3.55M | 20.34M | 63.57M | 8.57M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":5.59,"profit":true},{"date":"2021-12-31","value":31.99,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.49,"profit":true}] |
Cost of Revenue | 8.11M | 9.87M | 11.38M | 14.57M | 8.89M | [{"date":"2019-12-31","value":55.64,"profit":true},{"date":"2020-12-31","value":67.73,"profit":true},{"date":"2021-12-31","value":78.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":61,"profit":true}] |
Gross Profit | (8.11M) | (9.87M) | 20.34M | 49.01M | (313.00K) | [{"date":"2019-12-31","value":-16.54,"profit":false},{"date":"2020-12-31","value":-20.13,"profit":false},{"date":"2021-12-31","value":41.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-0.64,"profit":false}] |
Gross Margin | (Infinity%) | (277.79%) | 100.00% | 77.08% | (3.65%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-277.79,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.08,"profit":true},{"date":"2023-12-31","value":-3.65,"profit":false}] |
Operating Expenses | 295.68M | 309.05M | 360.80M | 344.09M | 275.69M | [{"date":"2019-12-31","value":81.95,"profit":true},{"date":"2020-12-31","value":85.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.37,"profit":true},{"date":"2023-12-31","value":76.41,"profit":true}] |
Operating Income | (295.68M) | (309.05M) | (340.46M) | (280.51M) | (276.01M) | [{"date":"2019-12-31","value":-29568100000,"profit":false},{"date":"2020-12-31","value":-30905200000,"profit":false},{"date":"2021-12-31","value":-34046200000,"profit":false},{"date":"2022-12-31","value":-28051300000,"profit":false},{"date":"2023-12-31","value":-27600600000,"profit":false}] |
Total Non-Operating Income/Expense | 9.43M | 4.89M | 734.00K | 54.21M | 839.00K | [{"date":"2019-12-31","value":17.4,"profit":true},{"date":"2020-12-31","value":9.03,"profit":true},{"date":"2021-12-31","value":1.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.55,"profit":true}] |
Pre-Tax Income | (290.96M) | (306.61M) | (340.10M) | (228.29M) | (276.11M) | [{"date":"2019-12-31","value":-29096400000,"profit":false},{"date":"2020-12-31","value":-30660500000,"profit":false},{"date":"2021-12-31","value":-34009500000,"profit":false},{"date":"2022-12-31","value":-22829000000,"profit":false},{"date":"2023-12-31","value":-27611100000,"profit":false}] |
Income Taxes | 12.00K | 15.00K | 46.00K | 12.00K | 15.00K | [{"date":"2019-12-31","value":26.09,"profit":true},{"date":"2020-12-31","value":32.61,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.09,"profit":true},{"date":"2023-12-31","value":32.61,"profit":true}] |
Income After Taxes | (290.98M) | (306.62M) | (340.14M) | (228.30M) | (276.13M) | [{"date":"2019-12-31","value":-29097600000,"profit":false},{"date":"2020-12-31","value":-30662000000,"profit":false},{"date":"2021-12-31","value":-34014100000,"profit":false},{"date":"2022-12-31","value":-22830200000,"profit":false},{"date":"2023-12-31","value":-27612600000,"profit":false}] |
Income From Continuous Operations | (290.98M) | (306.62M) | (340.14M) | (228.30M) | (290.25M) | [{"date":"2019-12-31","value":-29097600000,"profit":false},{"date":"2020-12-31","value":-30662000000,"profit":false},{"date":"2021-12-31","value":-34014100000,"profit":false},{"date":"2022-12-31","value":-22830200000,"profit":false},{"date":"2023-12-31","value":-29024800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (290.98M) | (306.62M) | (340.14M) | (2.28B) | (276.13M) | [{"date":"2019-12-31","value":-29097600000,"profit":false},{"date":"2020-12-31","value":-30662000000,"profit":false},{"date":"2021-12-31","value":-34014100000,"profit":false},{"date":"2022-12-31","value":-228302000000,"profit":false},{"date":"2023-12-31","value":-27612600000,"profit":false}] |
EPS (Diluted) | (5.71) | (4.21) | (3.63) | (2.72) | (2.62) | [{"date":"2019-12-31","value":-571,"profit":false},{"date":"2020-12-31","value":-421,"profit":false},{"date":"2021-12-31","value":-363,"profit":false},{"date":"2022-12-31","value":-272,"profit":false},{"date":"2023-12-31","value":-262,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ATRA | |
---|---|
Cash Ratio | 0.43 |
Current Ratio | 0.59 |
Quick Ratio | 0.50 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ATRA | |
---|---|
ROA (LTM) | -57.48% |
ROE (LTM) | -2014.86% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ATRA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.63 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.63 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ATRA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.96 |
P/B | 1.97 |
Price/FCF | NM |
EV/R | 0.42 |
EV/Ebitda | NM |
PEG | NM |
Atara Biotherapeutics Inc (ATRA) share price today is $10.5
Yes, Indians can buy shares of Atara Biotherapeutics Inc (ATRA) on Vested. To buy Atara Biotherapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Atara Biotherapeutics Inc (ATRA) via the Vested app. You can start investing in Atara Biotherapeutics Inc (ATRA) with a minimum investment of $1.
You can invest in shares of Atara Biotherapeutics Inc (ATRA) via Vested in three simple steps:
The 52-week high price of Atara Biotherapeutics Inc (ATRA) is $39.5. The 52-week low price of Atara Biotherapeutics Inc (ATRA) is $6.5.
The price-to-earnings (P/E) ratio of Atara Biotherapeutics Inc (ATRA) is
The price-to-book (P/B) ratio of Atara Biotherapeutics Inc (ATRA) is 1.97
The dividend yield of Atara Biotherapeutics Inc (ATRA) is 0.00%
The market capitalization of Atara Biotherapeutics Inc (ATRA) is $59.61M
The stock symbol (or ticker) of Atara Biotherapeutics Inc is ATRA